Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Take Tell Us What YOU Think! Take The Body's Visitor Survey!
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

National News

Oregon Health & Science University Doing Trial of New HIV Drug

November 4, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Eighteen Oregonians are participating in the trial of a promising new drug to treat HIV. The experimental drug, T-20, stops individual viruses from reproducing, slowing the disease's progression. In that respect, it works like AZT. But T-20 works by interfering with an entirely different step in the virus' life cycle.

"There's really a lot of exciting work going on right now," said Dr. Mary O'Hearn, who is coordinating care for patients enrolled in the trial through Oregon Health & Science University in Portland, one of dozens of test sites worldwide. That work could put several new HIV drugs on the market in the next five years, said Dr. James Leggett, an infectious disease specialist with Providence Portland Medical Center.

For Portland AIDS activist Fred Schaich, T-20 has been a blessing -- if an annoying one. Like many of the more than 1,000 patients in the trial worldwide, he must carefully refrigerate his medicines, mix them and inject himself twice daily -- frequently moving injection sites because the shots can cause scarring. But T-20 has significantly strengthened his immune system and brought his viral load to a level undetectable on tests. Results like that give O'Hearn hope that the FDA will soon approve T-20 for sale.

Advertisement
Evidence from all the patients in the study, after 24 weeks of treatment, showed that those taking a mix of several HIV drugs and T-20 reduced the viral load twice as much, on average, as those taking several HIV drugs but not T-20. Researchers coordinating the trial are crunching data through 48 weeks of treatment, which the FDA will consider.

The T-20 trial marks the first time an Oregon site has taken part in early HIV drug trials, O'Hearn said.

Back to other CDC news for November 4, 2002

Previous Updates

Adapted from:
Associated Press
11.01.02

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
More News on T-20 (Enfuvirtide, Fuzeon)

 

Advertisement